Enrolling by invitationPhase 2NCT07266090

A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Viatris Pharmaceuticals Co., Ltd.
Intervention: cenerimod 4 mg(drug)
Enrollment: 15 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2026 – 2027

Study locations (7)

The First Affiliated Hospital Of Jinan University, Guangzhou, Guangdong, China
The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
First People's Hospital of Jiujiang, Jiujiang, Jiangxi, China
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Peking Union Medical College Hospital, Beijing, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07266090 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus →

← Back to all trials